Company Overview of Tocagen Inc.
Tocagen Inc. is a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of gene therapy products for the selective treatment of cancer. The company focuses on developing a treatment for high grade glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more dist...
3030 Bunker Hill Street
San Diego, CA 92109
Founded in 2007
Key Executives for Tocagen Inc.
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2014.
Tocagen Inc. Key Developments
Tocagen Inc. Names Jamey Skillings as Senior Vice President and Chief Medical Officer
Mar 25 14
Tocagen Inc. announced that Jamey Skillings, M.D., has been named Senior Vice President and Chief Medical Officer. Dr. Skillings joins the company from Pfizer, where she was most recently vice president of global medical affairs for oncology.
Tocagen Inc. Doses First Patient Intravenously in Clinical Trial of Selective Cancer Therapy, Toca 511 & Toca FC
Mar 11 14
Tocagen Inc. announced that the first patient has been dosed in its clinical trial investigating the intravenous administration of selective cancer therapy Toca 511 & Toca FC, in patients with recurrent high grade glioma (HGG) including glioblastoma multiforme (GBM, Grade 4 HGG), the most common and aggressive form of primary brain cancer. The multicenter, open-label study is evaluating the safety, tolerability and pharmacokinetics of ascending doses of Toca 511 administered intravenously before scheduled tumor removal. Toca 511 is also administered into the wall of the resection cavity at the time of tumor removal, followed by cycles of oral Toca FC. Removed tumor will be tested for the presence of Toca 511. Patients will be monitored for changes in clinical status and clinical response data will be collected. Toca 511 & Toca FC is an investigational gene therapy that is designed to selectively infect and kill cancer cells via a proposed dual mechanism of action: first, the Toca 511 virus selectively infects and mediates direct cancer cell killing via local production of 5-FU, a potent anticancer agent, and second, the immune system becomes activated selectively against the tumor resulting in long-term, systemic anticancer activity. The combination of Toca 511 (vocimagene amiretrorepvec) for injection and Toca FC (flucytosine) extended-release tablets, is being investigated in Phase I/II studies at leading centers across the United States in patients with recurrent high grade glioma, including glioblastoma multiforme (GBM). Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a prodrug activator gene called cytosine deaminase (CD) selectively to cancer cells. After allowing time for Toca 511 to spread through the tumor, those cancer cells expressing the CD gene can convert the antibiotic drug flucytosine into the anticancer drug 5-fluorouracil (5-FU). By producing 5-FU locally with CD, this technology has the potential to produce much higher intra-tumoral concentrations of 5-FU than can be currently attained with systemic administration. In addition to this initial, direct killing of cancer cells, preclinical data suggests a selective, local and systemic anticancer immune response without off-target toxicity, such as autoimmunity. The Toca 511 & Toca FC combination product is being investigated in three ascending dose trials in patients with recurrent high grade glioma.
Tocagen Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-26-2014 11:40 AM
Feb 23 14
Tocagen Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-26-2014 11:40 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|